ATG与抗CD3单克隆抗体在肾移植免疫诱导治疗中的比较研究  

Comparative Study on ATG and Anti-CD3 Monoclonal Antibody for Immune Induction Therapy after Kidney Transplantation

作　　者：韩聪祥[1] 谢庆祥[1] 李金雨[1] 林吓聪[1] 赵力[1] 黄宏伟[1] 

机构地区：[1]解放军第一七五医院,厦门大学附属东南医院泌尿外科,福建漳州363000

出　　处：《医学临床研究》2009年第2期206-209,共4页Journal of Clinical Research

基　　金：福建省自然科学基金资助项目（2006J0388）

摘　　要：[目的]比较抗人体胸腺细胞球蛋白（ATG）与抗CD3单克隆抗体在肾移植免疫诱导治疗中的效果。[方法]对比分析应用ATG（77例）与抗CD3单克隆抗体（24例）进行免疫诱导治疗的肾移植患者的临床资料。[结果]ATG组与抗CD3单克隆抗体组在术后1年急性排斥反应发生率、透析过渡比例、早期移植肾功能恢复、年人／肾存活率方面无显著性差异，而ATG组药物不良反应及术后继发感染率显著少于CD3单克隆抗体组（P〈0．05）。[结论]身体一般情况较好的患者可以考虑用抗CD3单克隆抗体治疗，而耐受力较差或老年患者宜使用ATG治疗以策安全。[Objective]To compare antihuman thymocyte globulin （ATG） with anti-CD3 monoclonal antibody for immune induction therapy after kidney transplantation. [Methods]The clinical data of the renal trans- plantation patients treated with ATG （n= 77） or anti-CD3 monoclonal antibody （n~ 24） were analyzed and compared. [Results] There was no significant difference in the acute rejection incidence, percentage of dialysis, early graft function recovery, the survival rate of patient and kidney within one year between the ATG group and anti-CD3 monoclonal antibody group, but there were fewer side effects and infections in ATG group （ P 〈0.05）. [Conclusion] ATG is preferable for induction immunosuppression after renal transplantation. It ean be taken into account to treat the patients in better constitution with anti-CD3 monoclonal antibody, but the patients in weak constitution or aged should be treated with ATG to ensure safety.

关 键 词：肾移植/免疫学 抗淋巴细胞血清 抗原 CD3 抗体 单克隆 

分 类 号：R699.2[医药卫生—泌尿科学]